StreetInsider.com News Articles

Defence Therapeutics CEO outlines three strategic priorities in letter

Tue, 08 Sep 2026 06:13:59 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) CEO Dr. Amie Phinney has published a letter to shareholders outlining the biotechnology company's strategic direction, according to a press release dated September 8, 2026.

Phinney, who recently assumed the role of president and CEO, identified three core development areas: Accum®-enhanced antibody-drug conjugates (ADCs), Accum®-enabled radiotherapeutics, and determining the path forward for the company's clinical-stage AccuTOX® program.

On the ADC front, the company stated it does not intend to compete with ADC developers but rather to partner with them. The commercial objective is to generate revenue through partnerships and licensing agreements, with proceeds intended to

Defence Therapeutics CEO outlines three strategic priorities in letter

Tue, 08 Sep 2026 06:13:59 -0400

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.

Dear Shareholders,

Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Dear Shareholders,

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Dear Shareholders,

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Dear Shareholders,

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 2026.

On March 6, 2026, the Company completed a non-brokered private placement in which it issued 17,445,455 units of the Company ("Units") at a price of $0.55 per unit for gross proceeds of $9,595,000.25 (the "Offering"). Of the

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

Mon, 31 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capability of the Accum^® platform, which is designed to facilitate intracellular transport for enhanced payload delivery.

The initiative reflects Defence's growing strategic focus on radiopharmaceuticals, a rapidly advancing area of precision oncology where the Company believes Accum^® has significant potential to create novel products

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

Mon, 31 Aug 2026 03:15:00 -0400

Defence Therapeutics names Ryan Simms as COO and radiopharmaceutical head

Mon, 17 Aug 2026 03:17:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Ryan Simms, PhD, as Chief Operating Officer and Head of Radiopharmaceutical Programs, according to a company statement.

Dr. Simms brings more than 20 years of experience in radiopharmaceutical development, spanning discovery through first-in-human clinical studies. He previously held leadership roles at Fusion Pharmaceuticals, where he directed chemistry, radiochemistry, clinical manufacturing, and external partnerships across multiple clinical-stage programs. Fusion Pharmaceuticals was acquired by AstraZeneca in 2024 for approximately $2 billion. Dr. Simms also held roles at Abdera Therapeutics and the Centre for Probe Development and Commercialization. He holds a PhD in

Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs

Mon, 17 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and development capabilities as it advances its radiopharmaceutical drug conjugate ("RDC") programs.

"Ryan brings more than 20 years of experience in advancing targeted radiopharmaceuticals from discovery through first-in-human clinical studies, combined with the operational leadership needed to translate complex science into executable development

Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs

Mon, 17 Aug 2026 03:15:00 -0400

Defence Therapeutics names Dr. Amie Phinney as CEO

Tue, 04 Aug 2026 03:17:10 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) announced the appointment of Dr. Amie Phinney as President and Chief Executive Officer, effective August 1, 2026.

Founder Sébastien Plouffe, who previously served as CEO, will transition to the role of Executive Chairman of the Board, where he will focus on corporate strategy, capital markets, business development, and governance.

Dr. Phinney joined Defence Therapeutics in July 2025 as a Strategy and Business Advisor and was appointed to the Board of Directors in September 2025. She holds a PhD in Biomedical Research from the University of Basel and an MBA from Lake Forest Graduate

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Tue, 04 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026.

As part of the leadership transition, Mr. Sébastien Plouffe, Founder and Chief Executive Officer, will now assume the position of Executive Chairman of the Board, where he will continue to play a critical leadership role in guiding the Company's strategic direction, financing initiatives,

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Tue, 04 Aug 2026 03:15:00 -0400

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Wed, 08 Jul 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development activities.

Hamilton has emerged as one of Canada's leading hubs for radiopharmaceutical innovation, bringing together world-class capabilities spanning isotope production, radiopharmaceutical discovery, translational research, GMP manufacturing, and clinical translation. Anchored by McMaster University, alongside internationally recognized institutions and a rapidly

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Wed, 08 Jul 2026 03:15:00 -0400

Defence Therapeutics to attend BIO International Convention 2026

Wed, 17 Jun 2026 03:17:08 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) plans to participate in the BIO International Convention 2026, scheduled for June 22-25 in San Diego, California, according to a company statement.

The Montreal-based biotechnology company said its team will be available at the conference to meet with pharmaceutical and biotechnology companies, investors, and potential collaborators to discuss partnership opportunities centered on its Accum® drug delivery platform.

Accum® is designed to enhance intracellular delivery through endosomal escape and improved targeting of cellular compartments. The platform is being applied to antibody-drug conjugates (ADCs) and radiopharmaceutical drug conjugates (RDCs).

Defence Therapeutics said it is seeking partnerships

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Wed, 17 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California.

Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and potential strategic collaborators interested in exploring partnership opportunities involving Defence's proprietary Accum^® platform.

Accum^® is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Wed, 17 Jun 2026 03:15:00 -0400

Accum^® is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being

Defence Therapeutics adds former Biogen executive to board

Wed, 03 Jun 2026 03:17:17 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) appointed Dr. John Beaver to its board of directors, the Montreal-based biotechnology company announced.

Dr. Beaver brings over 20 years of experience in pharmaceutical and biotechnology leadership roles. He most recently served as Vice President and Head of Global Biomarker Discovery & Development at Biogen, where he led biomarker and translational development activities for approximately 48 pipeline programs.

During his tenure at Biogen, Dr. Beaver contributed to biomarker-driven development strategies associated with FDA accelerated approvals in Alzheimer's disease and ALS. He previously held senior positions at AbbVie, where he served as Head of

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Wed, 03 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.

Dr. Beaver has held senior leadership positions at several leading biopharmaceutical companies, including Biogen, AbbVie, and GlaxoSmithKline, where he contributed to the advancement of innovative therapeutic programs across multiple disease areas. His extensive experience spans translational medicine, biomarker discovery and development,